Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Enanta Pharmaceuticals (ENTA) PT Raised to $38 at JPMorgan
August 8, 2017 8:45 AM EDTJPMorgan raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $38.00 (from $32.00) while maintaining a Overweight rating.
... MoreEnanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined
August 8, 2017 7:19 AM EDTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating following the company's 3Q. AbbVie's reported sales of $225M for Viekira were largely in line with estimates. Enanta earned $7.5M in royalty revenue on these sales, versus... More
Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
August 7, 2017 4:01 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.44), $0.04 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $8.14 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More